54. Harat, M.; Malkowski, B.; Makarewicz, R. Pre-irradiation tumour volumes defined by MRI and dual time-point FET-PET for the prediction of glioblastoma multiforme recurrence: A prospective study. *Radiother. Oncol.* **2016**, *120*, 241–247. [CrossRef]

55. Dissaux, G.; Dissaux, B.; Kabbaj, O.E.; Gujral, D.M.; Pradier, O.; Salaün, P.-Y.; Seizeur, R.; Bourhis, D.; Ben Salem, D.; Querellou, S.; et al. Radiotherapy target volume definition in newly diagnosed high grade glioma using 18F-FET PET imaging and multiparametric perfusion MRI: A prospective study (IMAGG). *Radiother. Oncol.* **2020**, *150*, 164–171. [CrossRef]

56. Hayes, A.R.; Jayamanne, D.; Hsiao, E.; Schembri, G.P.; Bailey, D.L.; Roach, P.J.; Khasraw, M.; Newey, A.; Wheeler, H.R.; Back, M. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. *Pract. Radiat. Oncol.* **2018**, *8*, 230–238. [CrossRef]

57. Galldiks, N.; Stoffels, G.; Ruge, M.I.; Rapp, M.; Sabel, M.; Reifenberger, G.; Erdem, Z.; Shah, N.J.; Fink, G.R.; Coenen, H.H.; et al. Role of O-(2-[^18F]-Fluoroethyl)-l-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma. *J. Nucl. Med.* **2013**, *54*, 2046–2054. [CrossRef]

58. Unterrainer, M.; Schweisthal, F.; Suchorska, B.; Wenter, V.; Schmid-Tannwald, C.; Fendler, W.P.; Schüller, U.; Bartenstein, P.; Tonn, J.-C.; Albert, N.L. Serial ^18 F-FET PET Imaging of Primarily ^18 F-FET-Negative Glioma: Does It Make Sense? *J. Nucl. Med.* **2016**, *57*, 1177–1182. [CrossRef]

59. Bashir, A.; Brennum, J.; Broholm, H.; Law, I. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[[^18F]fluoroethyl)-l-tyrosine positron emission tomography: A retrospective study. *J. Neurosurg.* **2018**, *130*, 451–464. [CrossRef]

60. Jeong, S.Y.; Lee, T.H.; Rhee, C.H.; Cho, A.R.; Il Kim, B.; Cheon, G.J.; Choi, C.W.; Lim, S.M. 3'-Deoxy-3'-[[^18F]fluorothymidine and O-(2-[[^18F]fluoroethyl)-L-tyrosine PET in Patients with Suspicious Recurrence of Glioma after Multimodal Treatment: Initial Results of a Retrospective Comparative Study. *Nucl. Med. Mol. Imaging* **2010**, *44*, 45–54. [CrossRef]

61. Jansen, N.L.; Suchorska, B.; Schwarz, S.B.; Eigenbrod, S.; Lutz, J.; Graute, V.; Bartenstein, P.; Belka, C.; Kreth, F.W.; Fougère, C.L. [[^18F]Fluoroethyltyrosine-Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma. *Mol. Imaging* **2013**, *12*, 7290.2012.00027. [CrossRef]

62. Puranik, A.D.; Rangarajan, V.; Dev, I.D.; Jain, Y.; Purandare, N.C.; Sahu, A.; Choudhary, A.; Gupta, T.; Chatterjee, A.; Moiyadi, A.; et al. Brain FET PET tumor-to-white matter ratio to differentiate recurrence from post-treatment changes in high-grade gliomas. *J. Neuroimaging* **2021**, *31*, 1211–1218. [CrossRef] [PubMed]

63. Kertels, O.; Mihovilovic, M.I.; Linsenmann, T.; Kessler, A.F.; Tran-Gia, J.; Kircher, M.; Brumberg, J.; Monoranu, C.M.; Samnick, S.; Ernestus, R.-I.; et al. Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma with O-(2-[[^18F]fluoroethyl)-l-Tyrosine PET. *Clin. Nucl. Med.* **2019**, *44*, 695–701. [CrossRef] [PubMed]

64. Verger, A.; Filss, C.P.; Lohmann, P.; Stoffels, G.; Sabel, M.; Wittsack, H.-J.; Kops, E.R.; Galldiks, N.; Fink, G.R.; Shah, N.J.; et al. Comparison of O-(2-18 F-Fluoroethyl)-L-Tyrosine Positron Emission Tomography and Perfusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Patients with Progressive and Recurrent Glioma: A Hybrid Positron Emission Tomography/Magnetic Resonance Study. *World Neurosurg.* **2018**, *113*, e727–e737. [CrossRef]

65. Pyka, T.; Hiob, D.; Preibisch, C.; Gempt, J.; Wiestler, B.; Schlegel, J.; Straube, C.; Zimmer, C. Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI. *Eur. J. Radiol.* **2018**, *103*, 32–37. [CrossRef]

66. Werner, J.-M.; Weller, J.; Ceccon, G.; Schaub, C.; Tscherpel, C.; Lohmann, P.; Bauer, E.K.; Schäfer, N.; Stoffels, G.; Baues, C.; et al. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. *Clin. Cancer Res.* **2021**, *27*, 3704–3713. [CrossRef]

67. Galldiks, N.; Dunkl, V.; Stoffels, G.; Hutterer, M.; Rapp, M.; Sabel, M.; Reifenberger, G.; Kebir, S.; Dorn, F.; Blau, T.; et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[[^18F]fluoroethyl)-l-tyrosine PET. *Eur. J. Nucl. Med. Mol. Imaging* **2015**, *42*, 685–695. [CrossRef]

68. Werner, J.-M.; Stoffels, G.; Lichtenstein, T.; Borggrefe, J.; Lohmann, P.; Ceccon, G.; Shah, N.J.; Fink, G.R.; Langen, K.-J.; Kabbasch, C.; et al. Differentiation of treatment-related changes from tumour progression: A direct comparison between dynamic FET PET and ADC values obtained from DWI MRI. *Eur. J. Nucl. Med. Mol. Imaging* **2019**, *46*, 1889–1901. [CrossRef]

69. Lohmann, P.; Elahmadawy, M.A.; Gutsche, R.; Werner, J.-M.; Bauer, E.K.; Ceccon, G.; Kocher, M.; Lerche, C.W.; Rapp, M.; Fink, G.R.; et al. FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation. *Cancers* **2020**, *12*, 3835. [CrossRef]

70. Kebir, S.; Fimmers, R.; Galldiks, N.; Schäfer, N.; Mack, F.; Schaub, C.; Stuplich, M.; Niessen, M.; Tzaridis, T.; Simon, M.; et al. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[[^18F]fluoroethyl)-L-Tyrosine PET. *Clin. Cancer Res.* **2016**, *22*, 2190–2196. [CrossRef]

71. Rachinger, W.; Goetz, C.; Pöpperl, G.; Gildehaus, F.J.; Kreth, F.W.; Holtmannspötter, M.; Herms, J.; Koch, W.; Tatsch, K.; Tonn, J.-C. Positron Emission Tomography with O-(2-[[^18F]fluoroethyl)-l-tyrosine versus Magnetic Resonance Imaging in the Diagnosis of Recurrent Gliomas. *Neurosurgery* **2005**, *57*, 505–511. [CrossRef] [PubMed]

72. Lohmeier, J.; Bohner, G.; Siebert, E.; Brenner, W.; Hamm, B.; Makowski, M.R. Quantitative biparametric analysis of hybrid 18F-FET PET/MR-neuroimaging for differentiation between treatment response and recurrent glioma. *Sci. Rep.* **2019**, *9*, 14603. [CrossRef]

73. Bashir, A.; Mathilde Jacobsen, S.; Mølby Henriksen, O.; Broholm, H.; Urup, T.; Grunnet, K.; Andrée Larsen, V.; Møller, S.; Skjøth-Rasmussen, J.; Skovgaard Poulsen, H.; et al. Recurrent glioblastoma versus late posttreatment changes: Diagnostic accuracy of O-(2-[[^18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET). *Neuro Oncol.* **2019**, *21*, 1595–1606. [CrossRef] [PubMed]
74. Steidl, E.; Langen, K.-J.; Hmeidan, S.A.; Polomac, N.; Filss, C.P.; Galldiks, N.; Lohmann, P.; Keil, F.; Filipski, K.; Mottaghy, F.M.; et al. Sequential implementation of DSC-MR perfusion and dynamic [¹⁸F]FET PET allows efficient differentiation of glioma progression from treatment-related changes. *Eur. J. Nucl. Med. Mol. Imaging* **2021**, *48*, 1956–1965. [CrossRef] [PubMed]

75. Pöpperl, G.; Götz, C.; Rachinger, W.; Schnell, O.; Gildehaus, F.J.; Tonn, J.C.; Tatsch, K. Serial O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. *Eur. J. Nucl. Med. Mol. Imaging* **2006**, *33*, 792–800. [CrossRef]

76. Müller, M.; Winz, O.; Gutsche, R.; Leijenaar, R.T.H.; Kocher, M.; Lerche, C.; Filss, C.P.; Stoffels, G.; Steidl, E.; Hattingen, E.; et al. Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression. *J. Neurooncol.* **2022**, *159*, 519–529. [CrossRef]

77. Mehrkens, J.H.; Pöpperl, G.; Rachinger, W.; Herms, J.; Seelos, K.; Tatsch, K.; Tonn, J.C.; Kreth, F.W. The positive predictive value of O-(2-[¹⁸F]fluoroethyl)-l-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. *J. Neurooncol.* **2008**, *88*, 27–35. [CrossRef]

78. Galldiks, N.; Stoffels, G.; Filss, C.; Rapp, M.; Blau, T.; Tscherpel, C.; Ceccon, G.; Dunkl, V.; Weinzierl, M.; Stoffel, M.; et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. *Neuro Oncol.* **2015**, *17*, 1293–1300. [CrossRef]

79. Pöpperl, G.; Götz, C.; Rachinger, W.; Gildehaus, F.-J.; Tonn, J.-C.; Tatsch, K. Value of O-(2-[¹⁸F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma. *Eur. J. Nucl. Med. Mol. Imaging* **2004**, *31*, 1464–1470. [CrossRef]

80. Mütther, M.; Koch, R.; Weckesser, M.; Sporns, P.; Schwindt, W.; Stummer, W. 5-Aminolevulinic Acid Fluorescence-Guided Resection of 18F-FET-PET Positive Tumor Beyond Gadolinium Enhancing Tumor Improves Survival in Glioblastoma. *Neurosurgery* **2019**, *85*, E1020–E1029. [CrossRef]

81. Suchorska, B.; Unterrainer, M.; Biczok, A.; Sosnova, M.; Forbrig, R.; Bartenstein, P.; Tonn, J.-C.; Albert, N.L.; Kreth, F.-W. 18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy. *J. Neurooncol.* **2018**, *139*, 721–730. [CrossRef] [PubMed]

82. Galldiks, N.; Langen, K.-J.; Holy, R.; Pinkawa, M.; Stoffels, G.; Nolte, K.W.; Kaiser, H.J.; Filss, C.P.; Fink, G.R.; Coenen, H.H.; et al. Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI. *J. Nucl. Med.* **2012**, *53*, 1048–1057. [CrossRef] [PubMed]

83. Suchorska, B.; Jansen, N.L.; Linn, J.; Kretzschmar, H.; Janssen, H.; Eigenbrod, S.; Simon, M.; Pöpperl, G.; Kreth, F.W.; La Fougere, C.; et al. Biological tumor volume in ¹⁸FET-PET before radiochemotherapy correlates with survival in GBM. *Neurology* **2015**, *84*, 710–719. [CrossRef] [PubMed]

84. Jansen, N.L.; Suchorska, B.; Wenter, V.; Eigenbrod, S.; Schmid-Tannwald, C.; Zwergal, A.; Niyazi, M.; Drexler, M.; Bartenstein, P.; Schnell, O.; et al. Dynamic ¹⁸F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients. *J. Nucl. Med.* **2014**, *55*, 198–203. [CrossRef] [PubMed]

85. Thon, N.; Kunz, M.; Lemke, L.; Jansen, N.L.; Eigenbrod, S.; Kreth, S.; Lutz, J.; Egensperger, R.; Giese, A.; Herms, J.; et al. Dynamic ¹⁸F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. *Int. J. Cancer* **2015**, *136*, 2132–2145. [CrossRef]

86. Kunz, M.; Albert, N.L.; Unterrainer, M.; la Fougere, C.; Egensperger, R.; Schüller, U.; Lutz, J.; Kreth, S.; Tonn, J.-C.; Kreth, F.-W.; et al. Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas. *Neuro Oncol.* **2019**, *21*, 274–284. [CrossRef]

87. Ceccon, G.; Lohmann, P.; Werner, J.-M.; Tscherpel, C.; Dunkl, V.; Stoffels, G.; Rosen, J.; Rapp, M.; Sabel, M.; Herrlinger, U.; et al. Early Treatment Response Assessment Using ¹⁸F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy. *J. Nucl. Med.* **2021**, *62*, 918–925. [CrossRef]

88. Galldiks, N.; Dunkl, V.; Ceccon, G.; Tscherpel, C.; Stoffels, G.; Law, I.; Henriksen, O.M.; Muhic, A.; Poulsen, H.S.; Steger, J.; et al. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. *Eur. J. Nucl. Med. Mol. Imaging* **2018**, *45*, 2377–2386. [CrossRef]

89. Carles, M.; Popp, I.; Starke, M.M.; Mix, M.; Urbach, H.; Schimek-Jasch, T.; Eckert, F.; Niyazi, M.; Baltas, D.; Grosu, A.L. FET-PET radiomics in recurrent glioblastoma: Prognostic value for outcome after re-irradiation? *Radiat. Oncol.* **2021**, *16*, 46. [CrossRef]

90. Suchorska, B.; Giese, A.; Biczok, A.; Unterrainer, M.; Weller, M.; Drexler, M.; Bartenstein, P.; Schüller, U.; Tonn, J.-C.; Albert, N.L. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. *Neuro Oncol.* **2018**, *20*, 279–288. [CrossRef]

91. Wirsching, H.-G.; Roelcke, U.; Weller, J.; Hundsberger, T.; Hottinger, A.F.; von Moos, R.; Caparrotti, F.; Conen, K.; Remonda, L.; Roth, P.; et al. MRI and 18F-FET-PET predict survival benefit from bevacizumab plus radiotherapy in patients with IDH wild-type glioblastoma: Results from the randomized ARTE trial. *Clin. Cancer Res.* **2021**, *27*, 179–188. [CrossRef] [PubMed]

92. Sweeney, R.; Polat, B.; Samnick, S.; Reiners, C.; Flentje, M.; Verburg, F.A. O-(2-[¹⁸F]fluoroethyl)-l-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy. *Ann. Nucl. Med.* **2014**, *28*, 154–162. [CrossRef]

93. Pyka, T.; Gempt, J.; Ringel, F.; Hüttinger, S.; van Marwick, S.; Nekolla, S.; Wester, H.-J.; Schwaiger, M.; Förster, S. Prediction of Glioma Recurrence Using Dynamic 18F-Fluoroethyltyrosine PET. *AJNR Am. J. Neuroradiol.* **2014**, *35*, 1924–1929. [CrossRef] [PubMed]
94. Wollring, M.M.; Werner, J.-M.; Bauer, E.K.; Tscherpel, C.; Ceccon, G.S.; Lohmann, P.; Stoffels, G.; Kabbasch, C.; Goldbrunner, R.; Fink, G.R.; et al. Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. *Neuro Oncol.* **2022**, *25*, 984–994. [CrossRef]

95. Bauer, E.K.; Stoffels, G.; Blau, T.; Reifenberger, G.; Felsberg, J.; Werner, J.M.; Lohmann, P.; Rosen, J.; Ceccon, G.; Tscherpel, C.; et al. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[¹⁸F]-fluoroethyl)-l-tyrosine PET. *Eur. J. Nucl. Med. Mol. Imaging* **2020**, *47*, 1486–1495. [CrossRef] [PubMed]

96. Piroth, M.D.; Holy, R.; Pinkawa, M.; Stoffels, G.; Kaiser, H.J.; Galldiks, N.; Herzog, H.; Coenen, H.H.; Eble, M.J.; Langen, K.J. Prognostic impact of postoperative, pre-irradiation 18F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. *Radiother. Oncol.* **2011**, *99*, 218–224. [CrossRef]

97. Jansen, N.L.; Suchorska, B.; Wenter, V.; Schmid-Tannwald, C.; Todica, A.; Eigenbrod, S.; Niyazi, M.; Tonn, J.-C.; Bartenstein, P.; Kreth, F.-W.; et al. Prognostic Significance of Dynamic ¹⁸F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma. *J. Nucl. Med.* **2015**, *56*, 9–15. [CrossRef]

98. Moller, S.; Law, I.; Munck Af Rosenschold, P.; Costa, J.; Poulsen, H.S.; Engelholm, S.A.; Engelholm, S. Prognostic value of 18F-FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial. *Radiother. Oncol.* **2016**, *121*, 132–137. [CrossRef]

99. Dissaux, G.; Basse, V.; Schick, U.; EL Kabbaj, O.; Auberger, B.; Magro, E.; Kassoul, A.; Abgral, R.; Salaun, P.-Y.; Bourhis, D.; et al. Prognostic value of 18F-FET PET/CT in newly diagnosed WHO 2016 high-grade glioma. *Medicine* **2020**, *99*, e19017. [CrossRef]

100. Piroth, M.D.; Pinkawa, M.; Holy, R.; Klotz, J.; Nussen, S.; Stoffels, G.; Coenen, H.H.; Kaiser, H.J.; Langen, K.J.; Eble, M.J. Prognostic Value of Early [¹⁸F]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma Multiforme. *Int. J. Radiat. Oncol. Biol. Phys.* **2011**, *80*, 176–184. [CrossRef]

101. Schneider, F.; Wolpert, F.; Stolzmann, P.; Albatly, A.A.; Kenkel, D.; Weller, J.; Weller, M.; Kollias, S.S.; Rushing, E.J.; Veit-Haibach, P.; et al. Prognostic value of O-(2-[¹⁸F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma. *Acta Oncol.* **2020**, *59*, 1357–1364. [CrossRef] [PubMed]

102. Kertels, O.; Kessler, A.F.; Mihovilovic, M.I.; Stolzenburg, A.; Linsenmann, T.; Samnick, S.; Brändlein, S.; Monoranu, C.M.; Ernestus, R.-I.; Buck, A.K.; et al. Prognostic Value of O-(2-[¹⁸F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma. *Mol. Imaging Biol.* **2019**, *21*, 1174–1181. [CrossRef] [PubMed]

103. Floeth, F.W.; Pauleit, D.; Sabel, M.; Stoffels, G.; Reifenberger, G.; Riemenschneider, M.J.; Jansen, P.; Coenen, H.H.; Steiger, H.-J.; Langen, K.-J. Prognostic Value of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma. *J. Nucl. Med.* **2007**, *48*, 519–527. [CrossRef] [PubMed]

104. Niyazi, M.; Jansen, N.; Ganswindt, U.; Schwarz, S.B.; Geisler, J.; Schnell, O.; Büsing, K.; Eigenbrod, S.; La Fougère, C.; Belka, C. Re-irradiation in recurrent malignant glioma: Prognostic value of [¹⁸F]FET-PET. *J. Neurooncol.* **2012**, *110*, 389–395. [CrossRef]

105. Albert, N.L.; Galldiks, N.; Ellingson, B.M.; van den Bent, M.J.; Chang, S.M.; Cicone, F.; de Groot, J.; Koh, E.-S.; Law, I.; Rhun, E.L.; et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): A report of the RANO group. *Lancet Oncol.* **2024**, *25*, e29–e41. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.